

ANTAEUS

BIOSCIENCES

Medicine for Human Resilience

Recover proven pharmacological ideas.
Rebuild them in America.
Engineer what comes next.



Modern medicine has a resilience gap

**Disease is treated.
Capability under stress is
underserved.**

01 **HEAT**

02 **FATIGUE**

03 **HYPOXIA**

04 **SLEEP LOSS**

05 **TOXIC EXPOSURE**

06 **SUSTAINED WORKLOAD**

Defense | maritime | energy | mining | emergency response | aviation and space

The question is old. The development opportunity is new.



The science exists. The modern development does not.

01

RECOVER

Identify overlooked pharmacology

02

REPATRIATE

Build U.S. chemistry and API

03

VALIDATE

Reproduce findings to modern standards

04





IMPROVE

Optimize formulation, PK and delivery

05

ENGINEER

Create proprietary successors



U.S. supply-chain capability and drug development become one strategy.

Historical compounds can accelerate meaningful data

START WITH MORE THAN A BLANK SHEET

- 01 Known chemical starting points
- 02 Historical human exposure
- 03 Published efficacy signals
- 04 Manufacturing routes
- 05 Modern characterization gaps
- 06 Formulation and analogue IP

CREDIBILITY REQUIRES THE CAVEAT

Historical use does not establish U.S. safety or efficacy and does not replace appropriate FDA development.


The advantage is a better starting hypothesis, not a regulatory shortcut.

ATLAS turns historical pharmacology into proprietary medicines



OLD MOLECULE > U.S. DEVELOPMENT > PROPRIETARY SUCCESSOR

Discovery is only half the mission



Domestic. Controllable. Aligned with strategic customers.

Antaeus does not need to own every factory. It needs a reliable American development chain.

One resilience platform, three development paths

01

ATLAS

ENDURE

Resilience pharmacology
Actoprotector validation
Next-generation small molecules

02

AEGIS

PROTECT

Industrial toxicology
Medical countermeasures
Hazardous environments

03

PHOENIX

RECOVER

Mitochondrial medicine
Neuroprotection
Peptide therapeutics

ENDURE

>

PROTECT

>

RECOVER


AEGIS targets the pharmacology of toxic environments

100 ppm

NIOSH IDLH FOR H₂S

Rapid toxicity. Neurological injury. Respiratory failure. Limited treatment options.

**ATLAS IDENTIFIES
RESILIENCE BIOLOGY**



**AEGIS ASKS WHETHER THAT BIOLOGY
CAN BECOME A PURPOSE-BUILT
COUNTERMEASURE**

Oil and gas | maritime | mining | chemical operations | first response

Government can be customer, partner and capital source




A blended model can de-risk therapeutic development without making government an afterthought.

PHOENIX uses historical biology to engineer the long game



NOT A CATALOG OF OLD PEPTIDES. A DISCOVERY ENGINE FOR NEW ONES.

The platform compounds learning into pharmaceutical value



Consumer health is a byproduct, not the core thesis

ANTAEUS BIOSCIENCES

Drug development
Government and industrial
applications
Proprietary therapeutics



ANTAEUS PERFORMANCE

Potential future consumer-health
subsidiary
Lawful ingredients and separate
products
Knowledge and brand spillover

SEPARATE PRODUCTS. SEPARATE REGULATORY LANE. CORE SCIENCE FIRST.

Each cycle makes the next therapeutic program stronger



DEFENSE

INDUSTRY

PHARMA

NON-DILUTIVE FUNDING + PARTNERSHIPS + PROPRIETARY VALUE

NEXT-GENERATION THERAPEUTICS

The company begins with lived exposure to the problem

- | | | |
|----|--------------------|---|
| 01 | MERCHANT MARINER | Tanker operations and physical energy markets |
| 02 | EXTREME CONDITIONS | Heat, fatigue, hazardous atmospheres and 6-on/6-off watches |
| 03 | THE LITERATURE | A forgotten research lineage asking the same operational question |
| 04 | ANTAEUS | Build the scientific team and modern development platform |

THE FOUNDER IDENTIFIES THE PROBLEM. THE SCIENTIFIC TEAM BUILDS THE SCIENCE.

A four-stage roadmap moves from archive to clinic

2026

FORM



Archive assembled
CSO and SAB recruited
U.S. synthesis established

2027

VALIDATE



Reference compounds
ATLAS replication
PK and ADME
AEGIS screening

2028

ENGINEER



Proprietary analogues
Government awards
Industrial partnerships
PHOENIX discovery

2029+

ADVANCE



Lead optimization
IND-enabling work
Clinical development

PLANNING ROADMAP - MILESTONES WILL ADAPT TO DATA, REGULATORY INPUT AND CAPITAL


The pre-seed round finances the platform-defining experiment

\$750K

PRE-SEED

NEXT-ROUND MILESTONE

Reproduce a resilience phenotype, establish mechanism and nominate the first proprietary program.



Finance the experiment that determines whether overlooked resilience pharmacology can become a proprietary American therapeutic platform.



**THE WEDGE IS
REDEVELOPMENT.**

**THE COMPANY IS
HUMAN RESILIENCE.**

Forgotten pharmacology > U.S.-made reference drugs > resilience biology > proprietary therapeutics

ANTAEUS BIOSCIENCES

info@antaeusbiosciences.com | antaeusbiosciences.com

Selected public sources and planning disclosures

01	ACTOPROTECTOR LINEAGE	The Pharmacology of Actoprotectors pmc.ncbi.nlm.nih.gov/articles/PMC3762282/
02	CHEMICAL THREATS	NIH CounterACT Program ninds.nih.gov/current-research/trans-agency-activities/counteract-program
03	H2S EXPOSURE	NIOSH Immediately Dangerous to Life or Health profile cdc.gov/niosh/idlh/7783064.html
04	MEDICAL COUNTERMEASURES	BARDA mission and CBRN portfolio medicalcountermeasures.gov/barda
05	DOMESTIC CAPABILITY	BARDA Core Services medicalcountermeasures.gov/barda/core-services

PROGRAMS, TIMELINES, BUDGETS AND DEVELOPMENT PATHS ARE FORWARD-LOOKING PLANNING ASSUMPTIONS.